Iakushkin V V, Orekhov A N
Biokhimiia. 1992 Nov;57(11):1684-92.
Effects of two Ca-antagonists, verapamil and nifedipine, on the total cellular cholesterol content and accumulation, as well as on the synthesis and hydrolysis of cholesteryl esters in human aortic intimal smooth muscle cells and P388D1 cell line have been studied. Verapamil and nifedipine used at 10(-6) M and higher concentrations decreased the total cellular cholesterol content (by 25-40%) in intimal cells isolated from atherosclerotic lesions without any effect on the cholesterol content in normal intimal cells or P388D1 cells. At 2 x 10(-5) M verapamil and nifedipine prevented the accumulation of cholesterol induced by atherogenic blood serum or atherogenic low density lipoproteins in both types of cells. At 10(-5) M and higher concentrations verapamil and nifedipine inhibited (2-3-fold) cholesteryl ester synthesis in intimal cells and, used at 10(-6) M and higher doses, in P388D1 cells as well. Verapamil and nifedipine (2 x 10(-5) M) enhanced the hydrolysis of cholesteryl esters in both types of cells. The Ca-channel agonist Bay K8644 had no effect on cholesteryl ester synthesis, nor did it suppress its inhibition by Ca-antagonist. The beta-receptor blocker propranolol induced the accumulation of cholesterol in intimal cells and inhibited the synthesis and hydrolysis of cholesterol esters in these cells. The data obtained suggest that the antiatherosclerotic action of Ca-blockers is determined by their ability to reduce the cellular cholesterol content which is suggested to be the result of enhanced hydrolysis of cellular cholesteryl esters.
研究了两种钙拮抗剂维拉帕米和硝苯地平对人主动脉内膜平滑肌细胞和P388D1细胞系中总细胞胆固醇含量和蓄积以及胆固醇酯合成与水解的影响。维拉帕米和硝苯地平在10⁻⁶M及更高浓度时,可降低从动脉粥样硬化病变分离的内膜细胞中的总细胞胆固醇含量(降低25% - 40%),而对正常内膜细胞或P388D1细胞中的胆固醇含量无任何影响。在2×10⁻⁵M时,维拉帕米和硝苯地平可阻止两种细胞中由致动脉粥样硬化血清或致动脉粥样硬化低密度脂蛋白诱导的胆固醇蓄积。在10⁻⁵M及更高浓度时,维拉帕米和硝苯地平抑制内膜细胞中胆固醇酯的合成(抑制2 - 3倍),在10⁻⁶M及更高剂量时,对P388D1细胞也有抑制作用。维拉帕米和硝苯地平(2×10⁻⁵M)可增强两种细胞中胆固醇酯的水解。钙通道激动剂Bay K8644对胆固醇酯合成无影响,也不抑制钙拮抗剂对其的抑制作用。β受体阻滞剂普萘洛尔可诱导内膜细胞中胆固醇蓄积,并抑制这些细胞中胆固醇酯的合成与水解。所获得的数据表明,钙阻滞剂的抗动脉粥样硬化作用取决于它们降低细胞胆固醇含量的能力,这被认为是细胞胆固醇酯水解增强的结果。